UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 29, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware13-5315170

(State of Incorporation)(I.R.S. Employer Identification No.)

66 Hudson Boulevard East, New York, New York 10001-2192

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Stock, $0.05 par valuePFENew York Stock Exchange

1.000% Notes due 2027PFE27New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes Nox

At October 30, 2024, 5,666,990,035 shares of the issuer s voting common stock were outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Comprehensive Income/(Loss)

Condensed Consolidated Balance Sheets

Condensed Consolidated Statements of Equity

Condensed Consolidated Statements of Cash Flows

Notes to Condensed Consolidated Financial Statements

10

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

39

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

60

Item 4.

Controls and Procedures

60

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

60

Item 1A.

Risk Factors

60

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

60

Item 3.

Defaults Upon Senior SecuritiesN/A

Item 4.

Mine Safety DisclosuresN/A

Item 5.

Other Information60

Item 6.

Exhibits

61

Signature

61

N/A = Not Applicable

DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 25, 2024 and August 27, 2023, and for U.S. subsidiaries is as of and for the three and nine months ended September 29, 2024 and October 1, 2023. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2023 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:

Indicates calculation not meaningful or results are greater than 100%

2023 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2023

AbbVie

AbbVie Inc.

Alexion

Alexion Pharma International Operations Limited, a subsidiary of AstraZeneca PLC

ALKanaplastic lymphoma kinase

Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

ATTR-CMtransthyretin amyloid cardiomyopathy

BiohavenBiohaven Pharmaceutical Holding Company Limited

BioNTechBioNTech SE

BiopharmaGlobal Biopharmaceuticals Business

BMSBristol-Myers Squibb Company

BODBoard of Directors

CDCU.S. Centers for Disease Control and Prevention

Cerevel or Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc.

Comirnaty(a)

Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; Comirnaty Omicron XBB.1.5; Comirnaty JN.1 and Comirnaty KP.2.

COVID-19novel coronavirus disease of 2019

Developed MarketsIncludes, but is not limited to, the following markets: Western Europe, Japan, Canada, Central Europe, Australia, Scandinavian countries, South Korea, the Balkans, New Zealand and Finland

DMD

Duchenne muscular dystrophy

EMAEuropean Medicines Agency

Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, the Middle East, certain Eastern European countries and Turkey

EPS

earnings per share

ESGEnvironmental, Social and Governance

EUEuropean Union

EUAemergency use authorization

Exchange ActSecurities Exchange Act of 1934, as amended

FASBFinancial Accounting Standards Board

FCPA

Foreign Corrupt Practices Act

FDAU.S. Food and Drug Administration

Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended September 29, 2024

GAAPGenerally Accepted Accounting Principles

GSKGSK plc

HaleonHaleon plc

HIPAAHealth Insurance Portability and Accountability Act of 1996

HospiraHospira, Inc.

HRR

homologous recombination repair

IPR&Din-process research and development

IRAInflation Reduction Act of 2022

IRSU.S. Internal Revenue Service

JVjoint venture

KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

LPSloss per share

mCRCmetastatic colorectal cancer

mCRPCmetastatic castration-resistant prostate cancer

mCSPCmetastatic castration-sensitive prostate cancer

MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations

MDLMulti-District Litigation

MeridianMeridian Medical Technologies, Inc.

Moody s

Moody s Ratings (formerly Moody s Investors Service)

mRNAmessenger ribonucleic acid

MylanMylan N.V.

NDA

New Drug Application

NimbusNimbus Therapeutics, LLC

nmCRPCnon-metastatic castration-resistant prostate cancer

nmCSPC

non-metastatic castration-sensitive prostate cancer

NSCLCnon-small cell lung cancer

ODToral disintegrating tablet

ORD

Oncology Research and Development

OTCover-the-counter

Paxlovid(a)

an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)

PC1Pfizer CentreOne

PharmaciaPharmacia LLC (formerly Pharmacia Corporation)

PP&E

Property, plant and equipment

PRD

Pfizer Research and Development

Prevnar familyIncludes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)

PsApsoriatic arthritis

QTDQuarter-to-date or three months ended

RArheumatoid arthritis

RCCrenal cell carcinoma

R&Dresearch and development

RSVrespiratory syncytial virus

S&PS&P Global (formerly Standard & Poor s)

SeagenSeagen Inc. and its subsidiaries

SECU.S. Securities and Exchange Commission

SNS

Strategic National Stockpile

Takeda

Takeda Pharmaceutical Company Limited

UCulcerative colitis

U.K.United Kingdom

U.S.United States

ViiVViiV Healthcare Limited

Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac

YTDYear-to-date or nine months ended

(a)Certain uses of Paxlovid and COVID-19 vaccines from BioNTech and Pfizer have not been approved or licensed by the FDA. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. Emergency uses of COVID-19 vaccines from Pfizer and BioNTech, including Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula), have been authorized for emergency use by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.

This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.

The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X (formerly known as Twitter) accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.

Certain of the products and product candidates discussed in this Form 10-Q are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Three Months EndedNine Months Ended

(MILLIONS, EXCEPT PER SHARE DATA)September 29,

2024October 1,

2023September 29,

2024October 1,

2023

Revenues:

Product revenues(a)

$15,417 $11,587 $38,731 $38,575

Alliance revenues(a)

1,900 1,645 6,140 5,672

Royalty revenues(a)

384 260 992 737

Total revenues17,702 13,491 45,864 44,984

Costs and expenses:

Cost of sales(b), (c)

5,263 9,269 11,942 17,391

Selling, informational and administrative expenses(b)

3,244 3,281 10,456 10,196

Research and development expenses(b)

2,598 2,711 7,787 7,864

Acquired in-process research and development expenses13 67 20 122

Amortization of intangible assets1,312 1,179 3,927 3,466

Restructuring charges and certain acquisition-related costs313 155 1,669 377

Other (income)/deductions net243 181 2,030 381

Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)4,715 (3,352)8,033 5,187

Provision/(benefit) for taxes on income/(loss)234 (964)393 (320)

Income/(loss) from continuing operations4,481 (2,388)7,640 5,507

Discontinued operations net of tax(8)12 4 11

Net income/(loss) before allocation to noncontrolling interests4,473 (2,376)7,644 5,518

Less: Net income attributable to noncontrolling interests8 6 23 30

Net income/(loss) attributable to Pfizer Inc. common shareholders$4,465 $(2,382)$7,621 $5,488

Earnings/(loss) per common share basic:

Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders$0.79 $(0.42)$1.35 $0.97

Discontinued operations net of tax

Net income/(loss) attributable to Pfizer Inc. common shareholders$0.79 $(0.42)$1.35 $0.97

Earnings/(loss) per common share diluted:

Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders$0.79 $(0.42)$1.34 $0.96

Discontinued operations net of tax

Net income/(loss) attributable to Pfizer Inc. common shareholders$0.78 $(0.42)$1.34 $0.96

Weighted-average shares basic5,667 5,646 5,663 5,642

Weighted-average shares diluted5,705 5,646 5,699 5,714

(a)See Note1A.

(b)Exclusive of amortization of intangible assets.

(c)See Note 13A.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)

(UNAUDITED)

Three Months EndedNine Months Ended

(MILLIONS)September 29,

2024October 1,

2023September 29,

2024October 1,

2023

Net income/(loss) before allocation to noncontrolling interests$4,473 $(2,376)$7,644 $5,518

Foreign currency translation adjustments, net131 (109)200 234

Unrealized holding gains/(losses) on derivative financial instruments, net(303)408 41 519

Reclassification adjustments for (gains)/losses included in net income/(loss)(a)

(175)(67)(334)73

(477)341 (293)593

Unrealized holding gains/(losses) on available-for-sale securities, net59 (83)(17)30

Reclassification adjustments for (gains)/losses included in net income/(loss)(b)

(6)51 80 (442)

54 (32)63 (411)

Reclassification adjustments related to amortization of prior service costs and other, net(27)(29)(83)(88)

Reclassification adjustments related to curtailments of prior service costs and other, net(2)(1)(2)(14)

(29)(30)(85)(102)

Other comprehensive income/(loss), before tax(322)170 (115)313

Tax provision/(benefit) on other comprehensive income/(loss)(157)36 (81)(17)

Other comprehensive income/(loss) before allocation to noncontrolling interests$(166)$134 $(35)$330

Comprehensive income/(loss) before allocation to noncontrolling interests$4,307 $(2,242)$7,609 $5,848

Less: Comprehensive income/(loss) attributable to noncontrolling interests(3)4 (2)23

Comprehensive income/(loss) attributable to Pfizer Inc.$4,310 $(2,247)$7,611 $5,826

(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.

(b)Reclassified into Other (income)/deductions net.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS)September 29,

2024December 31, 2023

(Unaudited)

Assets

Cash and cash equivalents$1,092 $2,853

Short-term investments8,860 9,837

Trade accounts receivable, less allowance for doubtful accounts: 2024 $465; 2023 $470

14,451 11,566

Inventories11,721 10,189

Current tax assets3,243 3,978

Other current assets3,855 4,911

Total current assets43,223 43,333

Equity-method investments8,582 11,637

Long-term investments2,180 3,731

Property, plant and equipment, less accumulated depreciation: 2024 $16,675; 2023 $16,045

18,541 18,940

Identifiable intangible assets59,986 64,900

Goodwill68,570 67,783

Noncurrent deferred tax assets and other noncurrent tax assets7,909 3,706

Other noncurrent assets10,486 12,471

Total assets$219,476 $226,501

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2024 $3,746; 2023 $2,254

$9,699 $10,350

Trade accounts payable5,314 6,710

Dividends payable 2,372

Income taxes payable2,877 2,349

Accrued compensation and related items3,383 2,776

Deferred revenues2,020 2,700

Other current liabilities19,917 20,537

Total current liabilities43,211 47,794

Long-term debt58,002 61,538

Pension and postretirement benefit obligations2,073 2,167

Noncurrent deferred tax liabilities2,158 640

Other taxes payable5,905 8,534

Other noncurrent liabilities15,569 16,539

Total liabilities126,918 137,213

Commitments and Contingencies

Common stock480 478

Additional paid-in capital93,477 92,631

Treasury stock(114,760)(114,487)

Retained earnings121,059 118,353

Accumulated other comprehensive loss(7,971)(7,961)

Total Pfizer Inc. shareholders equity92,286 89,014

Equity attributable to noncontrolling interests272 274

Total equity92,558 89,288

Total liabilities and equity$219,476 $226,501

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, June 30, 20249,592 $480 $93,197 (3,925)$(114,757)$116,596 $(7,816)$87,700 $275 $87,975

Net income/(loss)

4,465 4,465 8 4,473

Other comprehensive income/(loss), net of tax

(155)(155)(10)(166)

Cash dividends declared, per share: $

Common stock

Share-based payment transactions 281 (3)(2)276 276

Other(1)

Balance, September 29, 20249,592 $480 $93,477 (3,926)$(114,760)$121,059 $(7,971)$92,286 $272 $92,558

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, July 2, 20239,561 $478 $92,329 (3,916)$(114,482)$128,796 $(8,102)$99,019 $274 $99,293

Net income/(loss)

(2,382)(2,382)6 (2,376)

Other comprehensive income/(loss), net of tax135 135 (2)134

Cash dividends declared, per share: $

Common stock

Noncontrolling interests (8)(8)

Share-based payment transactions1 167 (4)(2)161 161

Other

Balance, October 1, 20239,562 $478 $92,496 (3,916)$(114,485)$126,411 $(7,966)$96,934 $270 $97,204

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20249,562 $478 $92,631 (3,916)$(114,487)$118,353 $(7,961)$89,014 $274 $89,288

Net income/(loss)

7,621 7,621 23 7,644

Other comprehensive income/(loss), net of tax(10)(10)(25)(35)

Cash dividends declared, per share: $0.84

Common stock(4,760)(4,760)(4,760)

Share-based payment transactions30 2 846 (10)(273)(155)420 420

Other(1)

Balance, September 29, 20249,592 $480 $93,477 (3,926)$(114,760)$121,059 $(7,971)$92,286 $272 $92,558

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20239,519 $476 $91,802 (3,903)$(113,969)$125,656 $(8,304)$95,661 $256 $95,916

Net income/(loss)

5,488 5,488 30 5,518

Other comprehensive income/(loss), net of tax338 338 (8)330

Cash dividends declared, per share: $0.82

Common stock (4,629)(4,629)(4,629)

Noncontrolling interests (8)(8)

Share-based payment transactions43 2 694 (12)(516)(104)77 77

Other

Balance, October 1, 20239,562 $478 $92,496 (3,916)$(114,485)$126,411 $(7,966)$96,934 $270 $97,204

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended

(MILLIONS)September 29,

2024October 1,

2023

Operating Activities

Net income before allocation to noncontrolling interests$7,644 $5,518

Discontinued operations net of tax4 11

Net income from continuing operations before allocation to noncontrolling interests7,640 5,507

Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:

Depreciation and amortization5,222 4,620

Asset write-offs and impairments1,080 499

Deferred taxes(1,706)(1,584)

Share-based compensation expense700 404

Benefit plan contributions in excess of expense/income(466)(467)

Inventory write-offs and related charges associated with COVID-19 products(a)

5,847

Other adjustments, net(455)(744)

Other changes in assets and liabilities, net of acquisitions and divestitures(5,992)(10,622)

Net cash provided by/(used in) operating activities6,023 3,460

Investing Activities

Purchases of property, plant and equipment(1,992)(2,863)

Purchases of short-term investments(3,957)(30,138)

Proceeds from redemptions/sales of short-term investments2,630 18,018

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less2,649 (6,102)

Purchases of long-term investments(75)(166)

Proceeds from redemptions/sales of long-term investments1,541 189

Proceeds from partial sale of investment in Haleon(b)

3,491

Acquisition of business, net of cash acquired

(25)

Other investing activities, net(13)(193)

Net cash provided by/(used in) investing activities4,275 (21,282)

Financing Activities

Proceeds from short-term borrowings8,175 14

Payments on short-term borrowings(7,774)

Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less

(2,590)(106)

Proceeds from issuance of long-term debt 30,831

Payments on long-term debt(2,250)(2,569)

Cash dividends paid(7,132)(6,932)

Other financing activities, net(455)(613)

Net cash provided by/(used in) financing activities(12,026)20,624

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

(37)(39)

Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents(1,765)2,764

Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period2,917 468

Cash and cash equivalents and restricted cash and cash equivalents, at end of period$1,152 $3,233

Supplemental Cash Flow Information

Cash paid during the period for:

Income taxes

$3,172 $2,907

Interest paid

1,833 1,153

Interest rate hedges31 98

(a) See Note 13A.

(b) See Note 2B.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2023 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.

These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2023 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 25, 2024 and August 27, 2023, and for U.S. subsidiaries is as of and for the three and nine months ended September 29, 2024 and October 1, 2023.

We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment. See Note 13A.

We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for:

in the first quarter of 2024, we reclassified royalty income (substantially all of which is related to Biopharma) from Other (income)/deductions net and began presenting Royalty revenues as a separate line item within Total revenues in our consolidated statements of operations, and reclassified the associated royalty receivables from Other current assets to Trade accounts receivable, less allowance for doubtful accounts in our consolidated balance sheet;

in the fourth quarter of 2023, we began presenting Product revenues and Alliance revenues as separate line items within Total revenues in our consolidated statements of operations; and

segment reporting and geographic information in connection with the commercial reorganization that went into effect on January 1, 2024 (see Note 13).

Business development activities, including the December 2023 acquisition of Seagen, impacted financial results in the periods presented. See Note 2 below, as well as Notes 1A and 2 in our 2023 Form 10-K.

B. New Accounting Standard Adopted in 2024

On January 1, 2024, we adopted a new accounting standard which clarifies that contractual sale restrictions are not considered in measuring equity securities at fair value. The new guidance is consistent with our existing policy; therefore, it had no impact on our consolidated financial statements.

C. Revenues and Trade Accounts Receivable

Customers Our prescription biopharmaceutical products, with the exception of Paxlovid in 2023, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sold Paxlovid globally to government agencies in 2023. Our vaccines in the U.S. are primarily sold directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Our vaccines outside the U.S. are primarily sold to government and non-government institutions. Certain products in our portfolio are subject to seasonality of demand and Paxlovid revenues trend with infection rates.

Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:

(MILLIONS)September 29,

2024December 31, 2023

Reserve against Trade accounts receivable, less allowance for doubtful accounts

$1,955 $1,770

Other current liabilities:

Accrued rebates8,252 5,546

Other accruals1,068 902

Other noncurrent liabilities

822 796

Total accrued rebates and other sales-related accruals$12,097 $9,014

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.

In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.

During the three and nine months ended September 29, 2024 and October 1, 2023, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2023 Form 10-K.

Note 2. Acquisition and Equity-Method Investment

A. Acquisition

Seagen On December 14, 2023 (the acquisition date), we acquired Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 per share in cash. The total fair value of the consideration transferred was $44.2 billion ($43.4 billion, net of cash acquired). The combination of certain Pfizer and Seagen entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps.

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, including adjustments made in the first nine months of 2024 (measurement period adjustments) with a corresponding change to goodwill. The estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as soon as possible but no later than one year from the acquisition date.

(MILLIONS)Amounts Recognized

as of Acquisition Date

(as previously reported as of December 31, 2023)

Measurement Period Adjustments(a)

Amounts Recognized as of Acquisition Date (as adjusted)

Working capital, excluding inventories

$736 $(114)$622

Inventories(b)

4,195 (891)3,304

Property, plant and equipment524 (234)290

Identifiable intangible assets, excluding in-process research and development(c)

7,970 (575)7,395

In-process research and development20,800 (50)20,750

Other noncurrent assets174 (96)77

Net income tax accounts

(6,123)1,332 (4,790)

Other noncurrent liabilities(167)(33)(200)

Total identifiable net assets28,108 (661)27,447

Goodwill16,126 661 16,787

Net assets acquired/total consideration transferred$44,234 $ $44,234

(a)The changes in the estimated fair values are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

(b)As adjusted, comprised of $1.2 billion current inventories and $2.1 billion noncurrent inventories.

(c)As adjusted, comprised mainly of $6.9 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.

The measurement period adjustments did not have a material impact on our earnings.

The following items are subject to change:

Amounts for certain balances included in working capital (excluding inventories), and certain legal contingencies, pending receipt of certain information that could affect provisional amounts recorded. We do not believe any adjustments for legal contingencies will have a material impact on our consolidated financial statements.

Amounts for identifiable intangible assets, inventories, contractual commitments, PP&E, and operating lease right-of-use assets and liabilities, pending finalization of valuation efforts and the completion of certain physical inventory counts.

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Amounts for income tax assets, receivables and liabilities, pending the filing of Seagen s pre-acquisition tax returns and the receipt of information, including but not limited to that from taxing authorities, which may change certain estimates and assumptions used.

The following table provides unaudited U.S. GAAP supplemental pro forma information as if the acquisition of Seagen had occurred on January 1, 2022:

Unaudited Supplemental

Pro Forma Consolidated Results

Three Months EndedNine Months Ended

(MILLIONS, EXCEPT PER SHARE DATA)October 1,

2023October 1,

2023

Revenues$14,140 $46,756

Net income/(loss) attributable to Pfizer Inc. common shareholders

(3,338)2,702

Diluted earnings/(loss) per share attributable to Pfizer Inc. common shareholders

(0.59)0.47

The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company s results of operations would have been had the acquisition occurred on January 1, 2022, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company may differ significantly from the pro forma adjustments reflected here due to many factors.

The unaudited supplemental pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of the assets acquired and the liabilities assumed from Seagen. The historical U.S. GAAP financial information of Pfizer and Seagen was adjusted, primarily for the following pre-tax adjustments for the three and nine months ended October 1, 2023:

Additional amortization expense of approximately $142 million and $427 million, respectively, related to the preliminary estimate of the fair value of identifiable intangible assets acquired.

Additional expense related to the preliminary estimate of the fair value adjustment to acquisition-date inventory estimated to have been sold of approximately $224 million and $673 million, respectively.

Additional estimated interest expense of approximately $114 million and $905 million, respectively, related to the debt issued by Pfizer and the commercial paper borrowings to partially finance the acquisition.

Elimination of interest income of approximately $474 million and $804 million, respectively, related to the debt issuance proceeds that were invested prior to the acquisition date and associated with money market funds under the assumption that a portion of these funds would have been liquidated to partially fund the acquisition.

The above adjustments were then adjusted for the applicable tax impact using an estimated weighted-average statutory tax rate applied to the applicable pro forma adjustments.

B. Equity-Method Investment

Haleon We owned 32% of Haleon as of December 31, 2023. In March 2024, we sold approximately 30% of our investment in Haleon through the sale of 791 million ordinary shares in a global public offering, and the sale of 102 million ordinary shares directly to Haleon, for total consideration of $3.5 billion. We recognized a gain on the sale of our Haleon shares of $150 million during the first quarter of 2024 in Other (income)/deductions net (see Note 4). After the share sale, we owned approximately 23% of the outstanding voting shares of Haleon as of September 29, 2024.

The fair value of our investment in Haleon as of September 29, 2024, based on quoted market prices of Haleon stock, was $11.0 billion. Haleon is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. We record our share of earnings from Haleon on a quarterly basis on a one-quarter lag in Other (income)/deductions net.

12

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table summarizes the change in the carrying value of our investment in Haleon:

Three Months EndedNine Months Ended

(MILLIONS)September 29,

2024October 1,

2023September 29,

2024October 1,

2023

Beginning carrying value reported in Equity-method investments

$7,796 $11,228 $11,451 $10,824

Carrying value of shares sold

(3,312)

Dividends

(55)(65)(212)(154)

Currency translation adjustments and other(a)

471 (446)341 (172)

Basis difference adjustments and amortization(b), (c)

10 (91)(1)

Pfizer share of Haleon investee capital transaction(b), (d)

46 (44)

Pfizer share of Haleon earnings(b)

88 122 224 341

Ending carrying value reported in Equity-method investments

$8,356 $10,838 $8,356 $10,838

(a)See Note 6.

(b)Included in Other (income)/deductions net.

(c)Adjustments in the nine months ended September 29, 2024 include (i) the impact of Haleon s brand divestitures and impairments of intangible assets and (ii) changes in Haleon s tax rates on intangible asset-related deferred tax liabilities.

(d)The nine months ended September 29, 2024 includes (i) a decrease of $91 million recorded in the second quarter of 2024 for Pfizer s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024 and (ii) an adjustment of $46 million recorded in the third quarter of 2024 for the impact of the reduction in Pfizer s ownership from approximately 32% to approximately 23% as applied to dividends with a record date in the first quarter of 2024, which were recognized in Haleon s second quarter 2024 financial statements.

Summarized financial information for Haleon for the three and nine months ending June 30, 2024, the most recent period available, and for the three and nine months ending June 30, 2023, is as follows:

Three Months EndedNine Months Ended

(MILLIONS)June 30,

2024June 30,

2023June 30,

2024June 30,

2023

Net sales$3,503 $3,490 $10,636 $10,379

Cost of sales(1,346)(1,323)(4,312)(4,211)

Gross profit$2,157 $2,167 $6,324 $6,168

Income from continuing operations400 403 1,019 1,133

Net income400 403 1,019 1,133

Income attributable to shareholders388 382 971 1,066

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

A. Realigning our Cost Base Program

In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. We expect costs associated with this multi-year effort to continue primarily through 2024 and to total approximately $2.3 billion, primarily representing cash expenditures for severance and implementation costs, of which $1.7 billion is associated with our Biopharma segment. From the start of this program through September 29, 2024, we incurred costs under this program of $1.8 billion, of which $1.4 billion is associated with our Biopharma segment (including $1.3 billion of restructuring charges).

B. Manufacturing Optimization Program

In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is focused on operational efficiencies and we expect costs for this first phase to total approximately $1.7 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. These costs will be recorded primarily in 2024, with cash outlays expected primarily in 2025 and 2026. From the start of this program through September 29, 2024, we incurred costs under this program of $1.3 billion, substantially all of which is restructuring costs for our Biopharma segment.

13

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

C. Key Activities

The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:

Three Months EndedNine Months Ended

(MILLIONS)September 29,

2024October 1,

2023September 29,

2024October 1,

2023

Restructuring charges/(credits):

Employee terminations$25 $16 $1,009 $77

Asset impairments111 40 177 45

Exit costs

82 15 145 44

Restructuring charges/(credits)(a)

217 71 1,331 165

Transaction costs(b)

5 5 14

Integration/pre-integration costs and other(c)

96 78 333 198

Restructuring charges and certain acquisition-related costs313 155 1,669 377

Net periodic benefit costs/(credits) recorded in Other (income)/deductions net

2 7 (7)

Additional depreciation asset restructuring recorded in our condensed consolidated statements of operations as follows(d):

Cost of sales6 5 11 27

Selling, informational and administrative expenses2 5

Total additional depreciation asset restructuring

8 5 16 28

Implementation costs recorded in our condensed consolidated statements of operations as follows(e):

Cost of sales30 16 95 43

Selling, informational and administrative expenses13 71 77 196

Research and development expenses33 29 66 59

Total implementation costs75 116 238 298

Total costs associated with acquisitions and cost-reduction/productivity initiatives$398 $276 $1,930 $696

(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $141 million for the three months ended September 29, 2024 (primarily including charges for our Realigning our Cost Base Program) and charges of $1.2 billion for the nine months ended September 29, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program and credits of $69 million for our Realigning our Cost Base Program). Amounts associated with our Biopharma segment for the three and nine months ended October 1, 2023 were not material.

(b)Represents external costs for banking, legal, accounting and other similar services.

(c)Represents external, incremental costs directly related to integrating acquired businesses, and in 2023 our then-proposed acquisition of Seagen, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the nine months ended October 1, 2023, integration/pre-integration costs and other were mostly related to our acquisitions of Biohaven and Global Blood Therapeutics, Inc. and our then-proposed acquisition of Seagen.

(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

The following summarizes the components and changes in restructuring accruals:

(MILLIONS)Employee

Termination

CostsAsset

Impairment

ChargesExit CostsAccrual

Balance, December 31, 2023(a)

$1,978 $ $11 $1,988

Provision/(credit)1,009 177 145 1,331

Utilization and other(b)

(867)(177)(144)(1,187)

Balance, September 29, 2024(c)

$2,120 $ $12 $2,132

(a)Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($663 million).

(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.

(c)Included in Other current liabilities ($1.1 billion) and Other noncurrent liabilities ($1.1 billion).

14

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 4. Other (Income)/Deductions Net

Components of Other (income)/deductions net include:

Three Months EndedNine Months Ended

(MILLIONS)September 29,

2024October 1,

2023September 29,

2024October 1,

2023

Interest income$(116)$(523)$(374)$(1,015)

Interest expense783 695 2,352 1,521

Net interest expense(a)

668 173 1,977 505

Net (gains)/losses recognized during the period on equity securities

(446)393 (129)709

Income from collaborations, out-licensing arrangements and sales of compound/product rights(1)(10)(25)(84)

Net periodic benefit costs/(credits) other than service costs(102)(92)(311)(260)

Certain legal matters, net(b)

45 71 422 246

Certain asset impairments(c)

349 264

Haleon equity method (income)/loss(d)

(150)(131)(102)(354)

Other, net(e)

228 (222)(153)(645)

Other (income)/deductions net$243 $181 $2,030 $381

(a)The increase in net interest expense in the third quarter of 2024 reflects (i) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023 and (ii) higher interest expense driven by the remaining balance of our $8 billion of commercial paper issued in the fourth quarter of 2023 as part of the financing for our acquisition of Seagen. The increase in net interest expense in the first nine months of 2024 reflects (i) higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as the remaining balance of the $8 billion of commercial paper issued in the fourth quarter of 2023, both part of the financing for our acquisition of Seagen and (ii) a decrease in interest income due to lower investment balances after completion of our $43.4 billion Seagen acquisition in December 2023.

(b)The third quarter and first nine months of 2024 primarily include certain product liability expenses related to products discontinued and/or divested by Pfizer. The third quarter of 2023 included legal obligations related to pre-acquisition matters and certain product liability expenses related to products discontinued and/or divested by Pfizer. The first nine months of 2023 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer and legal obligations related to pre-acquisition matters.

(c)The first nine months of 2024 include a $240 million intangible asset impairment charge, associated with our Biopharma segment that represents IPR&D related to a Phase 3 study for the treatment of DMD, which reflects unfavorable clinical trial results. The first nine months of 2023 primarily represented intangible asset impairment charges, including (i) $128 million associated with Other business activities, related to IPR&D and developed technology rights for acquired software assets and reflected unfavorable pivotal trial results and updated commercial forecasts, and (ii) $120 million associated with our Biopharma segment resulting from the discontinuation of a study related to an out-licensed IPR&D asset for the treatment of prostate cancer.

(d)See Note 2B.

(e)The third quarter and first nine months of 2024 primarily include, among other things, a charge of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program. The first nine months of 2024 also includes, among other things, a $150 million gain on the partial sale of our investment in Haleon in the first quarter of 2024 and dividend income of $183 million from our investment in ViiV. The third quarter and first nine months of 2023 included, among other things, a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion. The first nine months of 2023 included, among other things, dividend income of $213 million from our investment in ViiV and $211 million from our investment in Nimbus resulting from Takeda s acquisition of Nimbus s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary.

Additional information about the intangible assets that were impaired during 2024 follows:

Nine Months Ended

Fair Value(a)

September 29, 2024

(MILLIONS)AmountLevel 1Level 2Level 3Impairment

Intangible assets IPR&D(b)

$ $ $ $240

Intangible assets Developed technology rights(b)

102 102 109

Total

$102 $ $ $102 $349

(a)The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also Note 1E in our 2023 Form 10-K.

(b)Reflects intangible assets written down to fair value in 2024. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

15

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 5. Tax Matters

A. Taxes on Income/(Loss) from Continuing Operations

Our effective tax rate for continuing operations was 5.0% for the third quarter of 2024, compared to 28.8% for the third quarter of 2023, and was 4.9% for the first nine months of 2024, compared to (6.2)% for the first nine months of 2023. The effective tax rate for the third quarter of 2024 is primarily a result of the jurisdictional mix of earnings and, to a lesser extent, tax benefits related to the closing of IRS audits covering multiple tax years. The positive effective tax rate for the third quarter of 2023 reflects a tax benefit on a pre-tax loss. The increase in the effective tax rate for the first nine months ended September 29, 2024, compared to the first nine months ended October 1, 2023, was primarily due to the non-recurrence of tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years in the second quarter of 2023 partially offset by tax benefits related to the closing of the IRS audits covering multiple tax years.

We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The sixth annual installment was paid by its April 15, 2024 due date. The seventh annual installment is due April 15, 2025 and is reported in current Income taxes payable as of September 29, 2024. The remaining liability is reported in noncurrent Other taxes payable. Our obligations may vary due to the availability of attributes such as foreign tax and other credit carryforwards or carrybacks.

For the year ended December 31, 2023, our cash paid for income taxes, net of refunds, was $3.1 billion, of which $1.9 billion was paid in the U.S.

B. Tax Contingencies

We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.

The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. During the third quarter of 2024, we effectively settled the audit of Pfizer s federal income tax returns for years 2016-2018. Tax years 2019-2024 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2012.

See Note 5D in our 2023 Form 10-K.

C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)

Components of Tax provision/(benefit) on other comprehensive income/(loss) include:

Three Months EndedNine Months Ended

(MILLIONS)September 29,

2024October 1,

2023September 29,

2024October 1,

2023

Foreign currency translation adjustments, net(a)

$(50)$(28)$(7)$(33)

Unrealized holding gains/(losses) on derivative financial instruments, net(65)80 5 108

Reclassification adjustments for (gains)/losses included in net income/(loss)

(42)(5)(68)(16)

(107)75 (63)91

Unrealized holding gains/(losses) on available-for-sale securities, net7 (10)(2)4

Reclassification adjustments for (gains)/losses included in net income/(loss)

(1)6 10 (55)

7 (4)8 (51)

Reclassification adjustments related to amortization of prior service costs and other, net(6)(7)(20)(21)

Reclassification adjustments related to curtailments of prior service costs and other, net (1)1 (3)

(6)(7)(18)(24)

Tax provision/(benefit) on other comprehensive income/(loss)$(157)$36 $(81)$(17)

(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.

16

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests

The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:

Net Unrealized Gains/(Losses)Benefit Plans

(MILLIONS)Foreign Currency Translation Adjustments(a)

Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)

Balance, December 31, 2023

$(7,863)$(217)$(9)$128 $(7,961)

Other comprehensive income/(loss)(b)

232 (230)55 (67)(10)

Balance, September 29, 2024$(7,631)$(447)$46 $61 $(7,971)

(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.

(b)Foreign currency translation adjustments include net gains related to our equity-method investment in Haleon (see Note 2B) and net losses related to the impact of our net investment hedging program.

17

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 7. Financial Instruments

A. Fair Value Measurements

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:

September 29, 2024December 31, 2023

(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2

Financial assets:

Short-term investments

Equity securities with readily determinable fair values:

Money market funds$1,420 $ $1,420 $5,124 $ $5,124

Available-for-sale debt securities:

Government and agency non-U.S.

3,493 3,493 817 817

Government and agency U.S.

2,120 2,120 2,601 2,601

Corporate and other

1,236 1,236 982 982

6,849 6,849 4,400 4,400

Total short-term investments8,269 8,269 9,524 9,524

Other current assets

Derivative assets:

Interest rate contracts

1 1

Foreign exchange contracts

280 280 298 298

Total other current assets281 281 298 298

Long-term investments

Equity securities with readily determinable fair values(a)

1,368 1,368 2,779 2,772 7

Available-for-sale debt securities:

Government and agency non-U.S.

124 124

Corporate and other

6 6 26 26

6 6 150 150

Total long-term investments1,374 1,368 7 2,929 2,772 156

Other noncurrent assets

Derivative assets:

Interest rate contracts

192 192 144 144

Foreign exchange contracts

160 160 258 258

Total derivative assets352 352 402 402

Insurance contracts(b)

878 878 790 790

Total other noncurrent assets1,231 1,231 1,191 1,191

Total assets$11,154 $1,368 $9,787 $13,943 $2,772 $11,170

Financial liabilities:

Other current liabilities

Derivative liabilities:

Interest rate contracts$28 $ $28 $16 $ $16

Foreign exchange contracts

488 488 404 404